Cetrorelix

CHEMBL1200490 Phase 4 Onaylandı Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1431.0 g/mol
LogP
1.9
Phase
4

A synthetic decapeptide antagonist of gonadotropin-releasing hormone (GnRH) that rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), preventing premature ovulation during controlled ovarian stimulation for assisted reproduction. Unlike GnRH agonists, it does not cause an initial hormonal flare. It is administered by subcutaneous injection during in vitro fertilization cycles.

Moleküler Ağırlık

1431,0000 g/mol

LogP

1,90

TPSA

498,00 Ų

Lipinski RO5

Başarısız

Terapötik Alanlar

Etki Mekanizması

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

InChI

InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1

Molecular Formula

C70H92ClN17O14

HBD / HBA

16 / 16

Döndürülebilir Bağlar

38

Ağır Atomlar

102

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A synthetic decapeptide antagonist of gonadotropin-releasing hormone (GnRH) that rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), preventing premature ovulation during controlled ovarian stimulation for assisted reproduction. Unlike GnRH agonists, it does not cause an initial hormonal flare. It is administered by subcutaneous injection during in vitro fertilization cycles.

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Yes, Cetrorelix is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200490. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 25074887. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.